Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China by Yabo OuYang et al.
OuYang et al. Virology Journal 2013, 10:10
http://www.virologyj.com/content/10/1/10RESEARCH Open AccessNeutralization sensitivity of HIV-1 subtype B’ clinical
isolates from former plasma donors in China
Yabo OuYang1†, Jianping Sun1†, Yang Huang1, Lu Lu2,3, Weisi Xu1, Xintao Hu1, Kunxue Hong1, Shibo Jiang2,3,
Yiming Shao1* and Liying Ma1*Abstract
Background: HIV-1 subtype B’ isolates have been predominantly circulating in China. Their intra- and inter-subtype
neutralization sensitivity to autologous and heterologous plasmas has not been well studied.
Results: Twelve HIV-1 B’ clinical isolates obtained from patients were tested for their intra- and inter-subtype
neutralization sensitivity to the neutralization antibodies in the plasmas from patients infected by HIV-1 B’ and
CRF07_BC subtypes, respectively. We found that the plasmas from the HIV-1 B’-infected patients could potently
neutralize heterologous viruses of subtype B’ with mean ID50 titer (1/x) of about 67, but they were not effective in
neutralizing autologous viruses of subtype B’ with mean ID50 titer (1/x) of about 8. The plasmas from HIV-1
CRF07_BC-infected patients exhibited weak inter-subtype neutralization activity against subtype B’ viruses with ID50
titer (1/x) is about 22. The neutralization sensitivity of HIV-1 B’ isolates was inversely correlated with the neutralizing
activity of plasmas from HIV-1 B’-infected patients (Spearman’s r = −0.657, P = 0.020), and with the number of
potential N-glycosylation site (PNGS) in V1-V5 region (Spearman’s r = −0.493, P = 0.034), but positively correlated
with the viral load (Spearman’s r = 0.629, P = 0.028). It had no correlation with the length of V1-V5 regions or the
CD4+ T cell count. Virus AH259V has low intra-subtype neutralization sensitivity, it can be neutralized by 17b (IC50:
10μg/ml) and 447-52D (IC50: 1.6μg/ml), and the neutralizing antibodies (nAbs) in plasma AH259P are effective in
neutralizing infection by the primary HIV-1 isolates with different subtypes with ID50 titers (1/x) in the range of 32–396.
Conclusions: These findings suggest that the HIV-1 subtype B’ viruses may mutate under the immune pressure, thus
becoming resistant to the autologous nAbs, possibly by changing the number of PNGS in the V1-V5 region of the viral
gp120. Some of primary HIV-1 isolates are able to induce both intra- and inter-subtype cross-neutralizing antibody
responses.
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The HIV-1 epidemic remains unchecked in China. The
HIV-1 subtype B’ (Thailand variant of subtype B, also
known as Thai B [1,2]), is one of the predominant subtypes
circulating in former plasma donors (FPDs) who were
infected by HIV-1 in the contaminant plasma, mainly in
four provinces (Henan, Anhui, Hubei and Shanxi) of China
[3,4]. HIV-1 subtype B’ was divergent and formed a mono-
phyletic group which can be distinguished from the B* Correspondence: yshao@bbn.cn; mal@chinaaids.cn
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reproduction in any medium, provided the orsubtype found in North America, Europe and elsewhere in
the world. Some distinct signature mutation sites between
B’ and typical B subtype were found around the p17 and
V3 regions [1,5,6]. Previously, the HIV-1 CRF07_BC re-
combinant was mainly circulating among the intravenous
drug users (IDUs) in Xinjiang Uyghur Autonomous Region
of China and later spread throughout the entire country
[3,7]. CRF07_BC is derived from subtype B’ and Indian
subtype C lineages [8,9].
Neutralizing antibodies (nAbs) are likely to be a critical
component of protective immunity if a human immuno-
deficiency virus type 1 (HIV-1) vaccine is to be effective
[10]. Most individuals developed nAbs to their own virus
(autologous neutralization) within a few months of infec-
tion [11], whereas plasmas from chronically-infectedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neutralizing activities [12,13]. The development of cross-
reactive nAbs during HIV-1 infection correlates with dur-
ation of infection, higher plasma viral RNA load and lower
CD4+ T cell counts [13-15].
NAbs could not eradicate the invasive virions because of
the emergence of viral mutants resistant to autologous
nAbs, even while retaining their ability to neutralize heter-
ologous viruses of the same subtype (heterologous
neutralization) [16,17]. Some studies revealed the mechan-
isms that HIV-1 escaped from nAbs through extensions of
the variable loops of Env, protection of conserved regions
from antibody recognition, extensive glycosylation patterns
of Env, steric occlusion and conformational masking of re-
ceptor binding sites [10,16,18-20].
Envelope glycoprotein of HIV-1 is the target of nAbs,
HIV-1 primary isolates can evolve over time to escape from
autologous neutralization by increasing the level and/or
changing the pattern of glycosylation on the viral env
[21-23]. However, HIV-1 can evolve increased neutralization
sensitivity to broadly neutralizing monoclonal antibodies
(bnmAb) and that the spectrum of neutralization capacities
by bnmAb can be broader when studied in longitudinal
analysis [24].
Our previous study showed that the neutralizing anti-
body response and the prevalence of naturally occurring
cross-reactive neutralizing activity in chronically HIV-1
subtype B’ infected FPDs [25]. In this study, we aimed to
determine the intra- and inter-subtype neutralization
sensitivity (i.e., the sensitivity of an HIV-1 subtype to theFigure 1 Neighbor-joining tree depicting the genetic relationship am
sequences for classifying HIV-1 subtypes (in bold) and CRFs were included.
subtype B) and closer to B.CN.RL42 (Thai B’) based on the phylogenetic anaantibodies from patients infected by the same or differ-
ent HIV-1 subtype, respectively) of HIV-1 B’, which may
serve as a basis for designing an AIDS vaccine to prevent
HIV-1 subtype B’ infection.
Results
General characteristics of the study subjects and viral
subtypes
Viruses were isolated from the peripheral blood mono-
nuclear cells (PBMCs) of 12 HIV-1-infected patients,
who are FPDs from Anhui province of China. The sub-
jects’ mean age was 40 years (30–52 years), 6 (50%) of
them were woman. The mean CD4+ and CD8+ T cell
counts were 289 (48–561) and 1016 (468–1937) per μl
of whole blood, respectively. The mean plasma viral
load (VL) was 4.95 (3.86-5.74) log10 HIV-1 RNA copies
per ml.
Phylogenetic analysis of the gp120 region gene se-
quence confirmed that all HIV-1 isolates were HIV-1
subtype B’. The phylogenetic tree showed that they were
close to B.FR.HXB2 (HIV subtype B) and closer to B.CN.
RL42 (Thai B’, a clade of HIV-1 B) (Figure 1). The amino
acid (AA) lengths and numbers of PNGS in the V1-V5
regions were analyzed by comparing their HIV-1 gp120
sequences. The V1V2 (67±1.6) and V4 (32±0.6) regions
displayed a relative heterogeneity in lengths, whereas the
V3 loop (35±0), V5 (12±0), C2 (99±0), C3 (52±0.1) and
C4 (42±0.2) regions showed little length variation
(Figure 2a). The number of PNGS ranged from 22 to 28
in V1-V5 regions with little change in the number ofong the HIV-1 isolates. A number of commonly used reference
All the isolates from Anhui (AHxxxV) were close to B.FR.HXB2 (HIV-1
lysis of gp120 gene.
Figure 2 Length of the gp120 V1-V5 subregions and the
number of PNGS in the gp120 V1-V5 subregions. The values on
the y-axis indicate the length in amino acids (AA) (a) and the
number of PNGS (b) in the gp120 V1-V5 subregions of 12 HIV-1
subtype B’ isolates.
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V1V2, C2 and V4 (Figure 2b).Neutralization sensitivity of HIV-1 B’ isolates
The above 12 HIV-1 B’ isolates were tested for their
intra- and inter-subtype neutralization sensitivities to the
plasmas from patients infected by the same subtype
(HIV-1 B’) and different subtype (HIV-1 CRF07_BC), re-
spectively. As shown in Table 1, most HIV-1 B’ isolates
exhibited high intra-subtype neutralization sensitivity to
the heterologous plasmas from the HIV-1 B’-infected
patients with mean ID50 titer (1/x) of about 67, while
they were resistant to most autologous plasmas with
mean ID50 titer of ≤ 8 (shown as “―” in the table).
Interestingly, the neutralization sensitivity of HIV-1 B’
isolates was inversely correlated with the neutralizing ac-
tivity of the plasmas from the HIV-1 B’-infected patients
(Figure 3; r = −0.657, P = 0.020). Some isolates, such as
AH1597V and AH311V exhibited high neutralization
sensitivity to most plasmas from the HIV-1 B’-infectedpatients with mean ID50 titers (1/x) of about 104 and
207, respectively, while their corresponding plasmas,
AH1597P and AH311P, were not effective in neutralizing
most of these HIV-1 B’ isolates with mean ID50 titers
(1/x) of about ≤ 8 and 21, respectively. In contrast, some
of the isolates, such as AH259V and AH691V, had low
neutralization sensitivity to most plasmas from the HIV-1
B’-infected patients, with mean ID50 titers (1/x) about ≤ 8
and 8.2, respectively. However, their corresponding plas-
mas (i.e., AH259P and AH691P) were effective in neutral-
izing most of these HIV-1 B’ isolates, with mean ID50
titers (1/x) about 199 and 204, respectively (Table 1). The
sensitivity of these isolates to neutralization by VRC01
[26] that a well known broadly neutralizing monoclonal
antibodies (bnmAb) included as a control were studied. It
is showed that the neutralization sensitivity (IC50) of
AH259V, AH691V and AH096V to VRC01 were more
than a concentration of 10μg/ml (Table 1). The viral inter-
subtype neutralization sensitivity of the HIV-1 B’ iso-
lates to the plasmas derived from 8 patients infected
by HIV-1 CRF07_BC was determined. As shown in
Table 2, most of the HIV-1 B’ isolates displayed low
inter-subtype neutralization sensitivity to the plasmas
from those patients with mean ID50 titer (1/x) of
about 22. All these results suggest that some viruses
able to induce broad neutralizing antibody response
gain machinery to protect themselves from the attack
by the neutralizing antibodies.
12 plasmas from HIV-1 B’-infected patients were tested
against a panel of 16 Env-pseudotyped reference viruses,
including eight clade B strains (SVPB6, SVPB8, SVPB11,
SVPB13, SVPB14, SVPB16, SVPB17 and SVPB19) [27],
four C strains (SVPC5, SVPC10, SVPC13 and SVPC16)
[28] and four A strains (HIV-Q461, HIV-Q769, HIV-Q259
and HIV-Q842) [29]. We found that clade B reference
viruses were more easily neutralized by plasmas from
HIV-1 subtype B’ infected patients (mean ID50 titer (1/x):
91.7) as compared to clade C (mean ID50 titer (1/x): 57.0)
and clade A reference viruses (mean ID50 titer (1/x):
61.8). 5 of 12 subtype B’ plasma samples showed broad
neutralization activity against more than 80% of refer-
ence viruses, especially, the plasma samples AH259P,
AH691P and AH628P. The three plasma samples were
appeared high neutralization activity, whereas AH1597P
failed to neutralized any of the panel of viruses tested, which
was alike to the result of plasma samples against autologous
or heterologous isolates from the HIV-1 B’-infected patients
(Table 1 and Additional file 1: Table S1).
As shown in Table 1, 8/12 viruses (66.67%) used co-
receptor CCR5 for cell entry, while the remaining four
(33.33%) used both CCR5 and CXCR4. There was no
difference between the R5 and R5X4 viruses in intra-
subtype neutralization sensitivity (P = 0.126) or inter-
subtype neutralization sensitivity (P = 0.349).
Table 1 Neutralization sensitivity of the HIV-1 B’ isolates to the plasmas from HIV-1 B’ infected patients
Virus (co-receptor usage) Neutralizing activity (ID50 titer, 1/x) of plasma from HIV-1 B’ infected patients VRC01§
IC50(μg/mL)
ADS-J1#
(% Inhibition)AH096P AH104P AH259P AH311P AH374P AH968P AH419P AH628P AH634P AH691P AH1188P AH1597P Mean
AH096V (R5) 11 21 204 38 57 77 21 90 ― 50 ― ― 49.4 >10 63.9
AH104V (X4R5) 18 ― 119 14 12 ― 16 20 ― 98 ― ― 28.1 1.107 46.9
AH259V ( R5) ― ― ― ― ― ― ― ― ― ― ― ― ― >10 77.0
AH311V (X4R5) 22 40 ≥ 648 ― 18 58 214 ≥ 648 166 ≥ 648 ― ― 207.2 1.473 92.2
AH374V (X4R5) 19 19 122 19 ― ― 82 50 ― 501 127 ― 80.9 0.081 94.2
AH968V (R5) 26 78 167 20 39 ― 50 159 21 487 20 ― 90.3 0.693 86.4
AH419V (R5) ― ― 78 ― ― 10 ― ― ― ― ― ― 14.0 0.601 82.2
AH628V (R5) 10 10 148 ― 15 112 ― ― ― 38 ― ― 31.8 ND 86.6
AH634V (R5) ― ― 140 ― 65 120 20 ― ― 263 ― ― 55.3 ND 83.0
AH691V (R5) ― ― ― ― ― 10 ― ― ― ― ― ― 8.2 >10 81.3
AH1188V (X4R5) 14 50 474 88 132 231 24 240 17 239 ― ― 127.1 0.320 63.4
AH1597V (R5) 20 35 275 21 44 100 30 300 275 100 45 ― 104.4 ND 94.7
Mean 14.3 24.4 199.3 20.7 34.5 62.5 40.8 129 45.3 204.0 22.0 ―
SF33 (X4R5)* 206 156 ≥ 648 ≥ 648 ≥ 648 80 622 441 187 399 80 ≥ 648
Panel of Env-pseudotyped viruses&
Clade B (n=8) 28.9 48.8 103.1 28.9 82.0 102.9 84.5 143.0 61.6 359.4 36.8 ― 91.7
Clade C (n=4) 30.5 27.5 140.5 30.5 28.3 59.0 27.5 96.0 28.3 136.0 59.5 ― 57.0
Clade A (n=4) 28.3 ― 108.0 28.3 56.0 33.5 109.0 146.3 26.5 123.0 42.3 ― 61.8
The plasmas were tested at a series of 3-fold dilutions ranging from 1:8 to 1:648. “―” means that the neutralizing titer is “≤ 8”. For calculation, the ID50 titers (1/x) of ≤ 8 and ≥ 648 were treated as 8 and 648,
respectively. The neutralizing titers of plasmas against the autologous virus are marked in bold and italics. *A laboratory-adapted HIV-1 strain was included as a control. & The sensitivity of 12 plasmas were tested
against Env-pseudotyped viruses of reference viruses panels[27-29], which displayed mean of ID50 titers (1/x) in the table, and “―” means that the neutralizing titer is “≤ 20” in this section (detail showed in Additional















Figure 3 Correlation between the neutralization sensitivity of the HIV-1 B’ isolates and the neutralizing activity of the plasmas from
HIV-1 B’-infected patients. The intra-subtype neutralization sensitivity of the HIV-1 B’ isolates is inversely correlated with the neutralizing activity
of the plasmas from HIV-1 B’-infected patients against these isolates. P values (two-sided) and r values are based on Spearman’s rank test.
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HIV-1 B’ isolates with the clinical and gp120 features
The potential correlation between neutralization sensi-
tivity of the HIV-1 B’ isolates and the clinical features,
such as CD4+ T cell count and viral load (VL), or the
gp120 features, such as length of the gp120 V1-V5 sub-
regions and the number of PNGS in the V1-V5 sub-
regions of gp120, was analyzed with the Spearman rank
order correlation test. We found that the neutralizationTable 2 Neutralization sensitivity of the HIV-1 B’ isolates to th
Virus
(co-receptor usage)
Neutralizing activity (ID50 titer,
XJ256P XJ257P XJ0135P XJ6291
AH096V (R5) ― ― 10 10
AH104V (X4R5) ― ― ― ―
AH259V ( R5) ― ― ― ―
AH311V (X4R5) ― ― 10 ―
AH374V (X4R5) ― ― ― 368
AH968V (R5) ― ― ― ―
AH419V (R5) ― ― ― ―
AH628V (R5) ― ― ― ―
AH634V (R5) 20 ― ― 11
AH691V (R5) 16 ― ― ―
AH1188V (X4R5) 16 20 ― ―
AH1597V (R5) 18 ― 54 10
Mean 11.2 9.0 12.2 38.6
SF33(X4R5)* 160 ≥ 648 ― ―
The plasmas were tested at a series of 3-fold dilutions ranging from 1:8 to 1:648. “―
of ≤ 8 and ≥ 648 were treated as 8 and 648, respectively. *A laboratory-adapted HIsensitivity of the HIV-1 B’ isolates was positively corre-
lated with VL (Figure 4b; r = 0.629, P = 0.028), but in-
versely correlated with the number of PNGS in the
gp120 V1-V5 sub-regions (Figure 4d; r = −0.493, P =
0.034). No significant correlation was observed between
the neutralization sensitivity of the HIV-1 B’ isolates and
CD4+ T cell count (Figure 4a; r = −0.266, P = 0.404) or
the lengths of the gp120 V1-V5 sub-regions (Figure 4c,
r = −0.424, P = 0.170). These results suggest that thee plasmas from HIV-1 CRF07_BC infected patients
1/x) of plasma from HIV-1 CRF07_BC infected patients
P XJ6371P XJ0793P XJ1353P XJ1981P Mean
28 ― ― ― 11.0
13 ― ― ― 8.6
― ― ― ― ―
27 ― ― ― 10.6
― ― ― ― 53.0
35 ― ― ― 11.4
― ― ― ― ―
― ― 13 ― 8.6
18 ― 24 ― 13.1
― ≥ 648 41 22 94.9
20 10 29 24 16.9
21 ― 17 ― 18.0
16.8 61.5 15.0 10.5
236 304 56 316
” means that the neutralizing titer is “≤ 8”. For calculation, the ID50 titers (1/x)
V-1 strain was included as a control.
Figure 4 Correlation between neutralization sensitivity of the HIV-1 B’ isolates and both clinical and gp120 features. The potential
correlation between the neutralization sensitivity of the HIV-1 B’ isolates and CD4+ T cell count (a), viral load (b), length of the gp120 V1-V5
subregions (c), and the number of PNGS in the V1-V5 subregions in gp120 (d) was analyzed by Spearman rank order correlation test. The values
on the y-axis indicate the neutralization sensitivity (mean ID50 titer) of 12 HIV-1 subtype B’ isolates. P values (two-sided) and r values are based on
Spearman’s rank test.
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izing antibodies by increasing the number of PNGS in
the gp120 V1-V5 sub-regions.
Characterization of AH259V and AH259P
As mentioned above, AH259V could not be neutralized
by any of the 12 plasma samples collected from the
HIV-1 B’-infected patients, whereas AH259P could po-
tently neutralize 10 of the 11 heterologous HIV-1 B’. We
then tested the neutralization sensitivity to several other
known bnmAbs, including F105 [32], IgG1B12 [33], 17b
[34], 44752D [35] and 2F5 [36]. We found that F105,
IgG1B12 and 2F5 failed to neutralize AH259V at a con-
centration of 50μg/ml, whereas 17b and 447-52D can
neutralize AH259V with the values of 10 and 1.6μg/ml,
respectively (Figure 5a). Subsequently, we tested the
neutralizing activity of the plasma AH259P againstseveral primary HIV-1 isolates of different subtypes, in-
cluding 92RW002 (subtype A), 92US657 (subtype B),
93IN101 (subtype C), RU570 (subtype G), and BCF02
(group O). We observed that the nAbs in AH259P were
effective in neutralizing all HIV-1 strains tested with
ID50 titers (1/x) in the range of 32–396 (Figure 5b).
These results suggest that although AH259V virus has
low intra-subtype neutralization sensitivity, it can be
neutralized by some known bnmAbs and the nAbs in
AH259P are effective in neutralizing infection by the pri-
mary HIV-1 isolates with different subtypes. Using PL-
ELISA, the epitope specificities of antibodies in AH259P
were analyzed with overlapping synthetic peptides cover-
ing the sequences of the entire gp120 and both the
extracellular and transmembrane domains of gp41 (data
not shown). It is showed that the antibodies significantly
bound to five peptides, including p27 (gp120 C2 region),
Figure 5 Neutralization sensitivity of AH259V and neutralizing
activity of AH259P. The neutralization sensitivity of AH259V to the
broadly neutralizing monoclonal antibodies (F105, IgG1B12, 17b,
447-52D and 2F5) (a) and the neutralizing activity of AH259P against
the primary HIV-1 isolates, including 92RW002 (subtype A, R5),
92US657 (subtype B, R5), 93IN101 (subtype C, R5), RU570 (subtype G,
R5), and BCF02 (group O, R5) (b) were determined using a
neutralizing assay for HIV-1 infection in PBMCs as described in the
Methods. The dotted line indicated that (a) the initial concentration
of bnmAbs is ranging from 50μg/ml, and IC50 >50μg/ml were
treated as 50; (b) the initial dilutions of plasma is ranging from 1:8,
and the ID50 titers (1/x) of < 8 were treated as 8.
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(gp41 TM region) and p66 (gp41 TM region). However,
these epitopes may not be the targets for the neutraliz-
ing antibodies since most of the neutralizing epitopes in
HIV-1 Env are conformational, rather than linear [37].
Further characterization of AH259V and AH259P is
warranted.
Discussion
In the present study, we evaluated the intra-subtype
neutralization sensitivity of HIV-1 B’ isolates to the
neutralization antibodies in the plasmas derived from
patients from whom the viruses were isolated. We
demonstrated that these isolates possess high intra-subtype neutralization sensitivity to the heterologous
plasmas, but very low intra-subtype neutralization sensi-
tivity to the autologous plasmas, which is consistent with
the results from our previous study on the HIV-1
CRF07_BC recombinant [38]. These findings suggest
that most HIV-1 B’ viruses can induce neutralization re-
sponse, but they become resistant to autologous neutral-
izing antibodies, most likely by the immune escape
mechanism developed during disease progression. By
analyzing the neutralizing activity of consecutive patient
plasma against the sequentially obtained autologous
virus, Arendrup et al. [39] found that the development
of neutralization to the primary HIV-1 isolates was ac-
companied by emergence of escape virus with corre-
sponding reduced neutralization sensitivity to autologous
plasma. This may explain the apparent failure of the im-
mune system to control HIV infection. In this study, we
also showed that HIV-1 B’ isolates exhibit low inter-
subtype neutralization sensitivity to the antibodies in the
plasmas derived from the HIV-1 CRF07_BC-infected
patients (Table 2), which may caused from low cross-
reactive neutralizing activity in different subtype or the
different neutralization potency in same subtype.
According to previous reports, the antibody response
matures and becomes cross-neutralizing against diver-
gent HIV-1 in up to 10% of HIV-1-infected patients, as
shown in neutralization assays [40,41]. Interestingly, we
found that the antibodies in some HIV-1 B’-infected
patients have potent cross-neutralizing activity. 5 of 12
subtype B’ plasma samples showed broad neutralization
activity against more than 80% of Env-pseudotyped
reference viruses that covered HIV-1 clade B, C and A.
And specially, the antibodies in AH259P could potently
neutralize infection of PBMCs by a series of primary
HIV-1 isolates with different subtypes (Figure 5b), while
the AH259V virus was shown to be sensitive to
neutralization by two known bnmAbs in this study
(Figure 5a). VRC01 failed to neutralize AH259V, AH691V
and AH096V at a concentration of 10μg/ml (Table 1). It is
reported that many HIV-1 strains in China were resistant
to PG9, PG16 and VRC01, which known to possess ex-
ceedingly high potency and breadth against diverse viruses
from outside China [42]. These findings suggest that al-
though most HIV-1 B’ viruses have low inter-subtype
neutralization sensitivity, some of these primary HIV-1
isolates are able to induce both intra- and inter-subtype
cross-neutralizing antibody responses.
It is reported that X4 HIV-1 viruses are generally more
sensitive than R5 viruses to neutralizing antibodies [43].
Most HIV-1 B’ primary HIV-1 isolates collected from
the FPDs were R5 viruses, while a few of them were
dual-tropic R5X4 viruses. In our study, no significant
difference in intra- and inter-subtype neutralization sen-
sitivity between the R5 and R5X4 viruses was observed,
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use CCR5 co-receptor for infection.
Positive correlation was shown between neutralization
sensitivity of the HIV-1 B’ isolates and viral load in
patients from whom the viruses were isolated, but no
significant correlation between viral neutralization sensi-
tivity and CD4+ T cell count in these patients was
observed. Notably, the neutralization sensitivity of HIV-
1 B’ isolates is inversely correlated with neutralizing ac-
tivity of plasmas from the HIV-1 B’-infected patients
(Figure 3), and with the number of PNGS in the V1-V5
sub-regions of gp120 (Figure 5d). This finding agrees
with the reports of others showing that the decreased
neutralization sensitivity of HIV-1 isolates results from
increased glycan numbers in the viral env used to build
up a “glycan shield” to protect the virus from attack by
neutralizing antibodies [44,45]. Interestingly, increase in
the number of PNGS is generally located in the gp120
variable regions of the neutralization-resistant isolates.
AH259V, for instance, has 10 PNGS in V1-V2 region,
while other viruses (e.g., AH1597V) with less resistance
have 5 PNGS in the same region.
Dhillon et al. [46] characterized the neutralization
antibody present in the plasma of three individuals
infected with subtype A and B viruses and found that
the highly conserved neutralizing epitope in gp41 and
highly variable V3 loop in gp120 may not account for
the broad neutralizing activity, while the CD4 binding
site in gp120 may be responsible for eliciting the
neutralization antibody. We will use similar approaches
to further investigate how the HIV-1 subtypes predom-
inant in China induce intra-subtype neutralizing anti-
body response and protect themselves from attack by
the autologous neutralizing antibodies. These studies may
provide a sound scientific platform for the rational design
of vaccines that induce antibody responses against the
HIV-1 isolates circulating in China.
Conclusions
The results from this study indicate that the HIV-1 B’ clin-
ical isolates retain their neutralization sensitivity to the
antibodies in the heterologous plasmas, but become resist-
ant to those in autologous plasmas. Their neutralization
sensitivity is inversely correlated with the neutralizing ac-
tivity of nAbs from the patients infected by the same sub-
type of HIV-1 and with the number of PNGS in the viral
gp120. The HIV-1 B’ clinical isolates lack the inter-
neutralization sensitivity to the neutralizing antibodies
from the patients infected by the HIV-1 CRF07_BC re-
combinant. These findings suggest that the HIV-1 B’
viruses may mutate under the immune pressure, thus be-
coming resistant to the autologous nAbs, possibly by
changing the number of PNGS in the V1-V5 region of the
viral gp120.Methods
Study population
The study population was selected from a multicenter
AIDS Cohort Study in China in 2005 and consisted of
pre-selected HIV-1-infected patients, who were naive to
antiretroviral therapies. All the patients had a self-
reported history of paid blood donation of more than 10
years. The blood samples from 12 of these cohort
patients were collected. Whole blood was used for CD4+
and CD8+ T cell counts and peripheral blood mono-
nuclear cells (PBMCs) were isolated by Ficoll-Paque gra-
dient (Amersham Biosciences, Uppsala, Sweden) for
HIV-1 isolation. Plasmas were separated by centrifuga-
tion from the citrated dextrose-treated blood samples
and stored at −20°C until use for detection of neutralizing
antibodies. We also collected plasmas from the HIV-1
CRF07_BC-infected IDUs in Xinjiang Uyghur Autono-
mous Region of China [38] as controls. This study was
approved by the Institutional Research Ethics Community
of Chinese Center for Disease Control and Prevention
(IRB00002276), and all subjects signed informed consent
to participate in the research study forms prior to blood
and data collection.
Detection of viral load (VL), CD4+ and CD8+ T cell count
Plasma VL was measured using the HIV-1 nucleotide
fluorescence quantitative assay kit (BD Biosciences,
Franklin Lakes, NJ) according to the manufacturer’s
instructions, which has a lower detection limit (LDL) of
500 copies/ml. The average CD4+ and CD8+ T lympho-
cyte counts were assessed by flow cytometry analysis
(BD Biosciences) [47].
Isolation of HIV-1 from patients’ PBMCs
Primary HIV-1 viruses were isolated from PBMCs as
previously described [39,48]. Briefly, PBMCs isolated
from HIV-1-infected individuals were co-cultured with phyto-
hemagglutinin (PHA)-stimulated PBMCs obtained from two
or more HIV-1-seronegative healthy donors. The cell cultures
were maintained for 4 weeks in RPMI 1640 medium (Gibco)
containing 20 U/ml of recombinant interleukin-2 (IL-2), 1%
penicillin and streptomycin, 2 mM glutamine, and 10% fetal
bovine serum (FBS). Culture medium was changed twice a
week. HIV-1 p24 was quantified using a commercial enzyme-
linked immunosorbent assay (ELISA) kit (BioMerieux,
France) once a week for 4 weeks. The viruses in the culture
supernatants with p24 > 2 ng/ml were harvested, titrated, and
stored in liquid nitrogen until used.
Amplification and genetic analysis of HIV-1 gp120 region
Viral RNA was extracted from the isolated viruses using
a QIAampW Viral RNA Mini Kit (Qiagen Inc., Chats-
worth, CA) according to the manufacturer’s protocol.
The region coding gp120 was amplified from viral RNA
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reaction was performed with the primers ES3 (50-GAA
TAAGAGAAAGAGCAgAAGA-30, 7219–7240) and eas1
(50-CTAGGAGCTGTTGATCCTTTAGGTA-30, 9005–9028).
The amplification was run at 50°C for 30 min, and 94°C
for 2 min followed by 40 cycles at 94°C for 30s, 62°C for
30 s (−0.3°C/cycle) and 72°C for 2 min, with a final exten-
sion of 72°C for 10min. A nested reaction was then
performed with the primers ES4 (50-CAGAAGACAG
TGGCAATGAGA-30, 7234–7254) and eas2 (50-GCC
TGTACCGTCAGCGTTATT -30, 8850–8870). The amp-
lification was run for 3 cycles at 94°C for 3min, 55°C for
50s, and 72°C for 90s, then followed by 30 cycles at 94°C
for 30s, 55°C for 50s and 72°C for 90s, with a final exten-
sion of 72°C for 10min (Gene Amp PCR System 9700, Ap-
plied Biosystems, Foster City, California, USA). PCR
products were gel-purified by using a QIAquick Gel Ex-
traction Kit (QIAGEN, Valencia, CA), then sequenced on
an ABI 3770 Sequencer (Applied Biosciences). Chromato-
grams were examined manually for the presence of double
peaks indicative of two templates per sequencing reaction.
Sequences were aligned using GeneCutter (http://www.
hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html)
and Clustal W together with selected subtypes/CRFs and
then additionally edited by hand when needed. Phylogenetic
analysis was performed using the neighbor-joining method
in MEGA5, and the reliability of the branching orders was
tested by bootstrap analysis of 1,000 replicates [49]. The
length of V1 to V5 (V1-V5) in the gp120 region was
analyzed using BioEdit software (version 7.1.3). Potential
N-linked glycosylation sites (PNGS) in V1-V5 were
predicted using the N-GLYCOSITE web tool from the Los
Alamos HIV database [44].Determination of viral co-receptor usage
The viral co-receptor usage of the primary HIV-1
isolates was determined as previously described [50].
Briefly, GHOST cells that express CD4 and CXCR4
(Ghost-X4) or CCR5 (Ghost-R5) were seeded in
24-well plates at the density of 1×105 cells/well over-
night. When about 70% confluent mono-layers,
GHOST cells were infected with virus stocks (200μl/
well) containing 8 μg/ml DEAE-dextran, which
enhance the infective efficiency. After 48 hours, cells
were harvested and analyzed with flow cytometey
(Elite ESP, Beckman Coulter, Germany). Approxi-
mately 10-fold shifts in mean GFP fluorescence of
infected cells over uninfected cell were considered as
positive for the corresponding co-receptor [51]. The
Ghost-R5 and Ghost-X4 cells infected with HIV-1SF33
(R5X4), HIV-1Ba-L (R5) and HIV-1IIIB (X4) were posi-
tive controls and the cells without HIV-1 infection
were negative control.NAb assay in TZM-bl cells
Neutralizing activities of plasma samples and bnmAbs
against isolates by a sensitive HIV-1 neutralization assay
using TZM-b1 cells were performed as previously
described [51,52]. Briefly, a primary HIV-1 isolate (200
TCID50) was pre-incubated in triplicate with a series of
3-fold diluted plasma or antibody, followed by incuba-
tion for 1h at 37°C. Plasma from HIV-1-seronegative
healthy blood donors was included as control. TZM-b1
cells (1×104 cells) in the presence of DEAE-dextran (15
μg/ml) were added to each well. After 48h incubation,
150 μl culture medium was removed from each well and
100μl luciferase reporter gene assay system reagent was
added (Bright-Glo; Promega). Following a short incuba-
tion (minimum of 2 min), 150 μl lysate from each well
was transferred to 96-well black solid plates for meas-
urement of luminescence in a luminometer (PerkinEl-
mer Life Sciences). Mock infected cells were used to
determine background luminescence. HIV-1 Env-pseu-
dotyped virus preparation, titration and nAbs assay in
TZM-bl cells were as described previously [25]. The
neutralizing activity was reported as the reciprocal of di-
lution (1/x) of plasma required to confer 50% inhibition
(ID50) of infection by the virus tested.
Neutralization of infection by primary HIV-1 isolates in
PBMCs
The neutralizing sensitivity of A259V to the broadly neu-
tralizing monoclonal antibodies and the neutralizing activ-
ity of A259P against primary HIV-1 isolates of different
subtypes were determined as previously described [53].
PBMCs were isolated from health blood donor by stand-
ard density gradient centrifugation using Histopaque-1077
(Sigma Chemical Co.). The cells were placed in a 75 cm2
plastic flask and incubated at 37°C for 2 hours. The non-
adherent cells were collected and resuspended at 5×106 in
10 ml RPMI-1640 medium containing 10% FBS, 5μg/ml
PHA (Sigma) and 100 U/ml IL-2 (Sigma), followed by in-
cubation at 37°C for 3 days. The PHA-stimulated cells
were infected with corresponding primary HIV-1 isolates
at 0.01 multiplicity of infection (MOI). Culture media
were changed every 3 days. The supernatants were col-
lected 10 days post-infection and tested for p24 antigen by
ELISA as previously described [53]. The percentage of in-
hibition of p24 production and the concentration for 50%
inhibition (IC50) was calculated as described before [52].
Linear antibody epitope mapping
The linear epitopes for the antibodies in AH259P were
mapped with overlapping synthetic peptides derived
from the sequence of the Env of SHIVchn19 (obtained
from the NIH Research and Reference Reagent Program)
using PLL-ELISA as previously described [54]. Briefly,
the peptides that were diluted to a concentration of
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coated with PLL (poly-L-leucine, 30–70 kDa, Sigma
Aldrich), followed by incubation at room temperature
for 1 h and washed with PBS. After addition of 1% glu-
taraldehyde (Sigma Aldrich), the plate was incubated at
room temperature for 15 min and washed twice with
PBS. The test plasma that were diluted at 1:400 in PBS
containing 5% skimmed dry milk were added into the
plates in duplicate and incubated at 37°C for 1 h, fol-
lowed by addition of HRP-linked anti-human IgG and
OPD substrate, sequentially. The OD value for each well
was read with an automated plate reader at 450 nm. An
OD value greater than two-fold average OD value of
background was considered as positive.
Statistical analysis
Correlations between neutralization sensitivity and vari-
ables were analyzed using a Spearman’s rank test (SPSS
software package, version 17.0), and a P value less than
0.05 was considered statistically significant.
Additional file
Additional file 1: Table S1. Neutralization activity of 12 plasmas against
a panel of 16 Env-Pseudotyped viruses.
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